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ABSTRACT
Introduction: Hypertension (HTN) is a leading risk
factor for preventable cardiovascular disease, with over
one in ﬁve adults affected worldwide. Lifestyle
modiﬁcation is a key strategy for the prevention and
treatment of HTN. Stress has been associated with
greater cardiovascular risk, and stress management is
a recommended intervention for hypertensives. Stress
reduction through relaxation therapies has been shown
to have an effect on human physiology, including
lowering blood pressure (BP). However, individualised
behavioural interventions are resource intensive, and
group stress management approaches have not been
validated for reducing HTN. The HARMONY Study is
a pilot randomised controlled trial designed to determine
if mindfulness-based stress reduction (MBSR),
a standardised group therapy, is an effective intervention
for lowering BP in stage 1 unmedicated hypertensives.
Methods and analysis: Men and women
unmedicated for HTN with mean daytime ambulatory
blood pressure (ABP) $135/85 mm Hg or 24 h ABP
$130/80 mm Hg are included in the study. Subjects
are randomised to receive MBSR immediately or after
a wait-list control period. The primary outcome
measure is mean awake and 24 h ABP. The primary
objective of the HARMONY Study is to compare ABP
between the treatment and wait-list control arm at the
12-week primary assessment period. Results from this
study will determine if MBSR is an effective intervention
for lowering BP in early unmedicated hypertensives.
Ethics and dissemination: This research project was
approved by the Sunnybrook Research Ethics Board
and the University Health Network Research Ethics
Board (Toronto, Canada). Planned analyses are in full
compliance with the principles of the Declaration of
Helsinki. Data collection will be completed by early
spring 2012. Primary and secondary analysis will
commence immediately after data monitoring is
completed; dissemination plans include preparing
publications for submission during the summer of
2012.
Trial registration number: This study is registered
with http://clinicaltrials.gov (NCT00825526). INTRODUCTION
Based on an annual consensus conference
reviewing the world literature including the
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ARTICLE SUMMARY
Article focus
- Does MBSR have a signiﬁcant BP-lowering effect
on awake and 24 h ABP?
- Is MBSR a safe and feasible complementary
treatment for high BP?
- Is there interest in the general population to
participate in a meditation/stress reduction
programme to lower high BP?
Key messages
- Results of this trial will contribute to the
development of non-pharmacological treatment
approaches to HTN.
- If a positive outcome is achieved, the HARMONY
Study could highlight MBSR as a new paradigm
for delivering lifestyle therapy.
- If successful, the next phase of the project will
incorporate additional lifestyle intervention
components to MBSR therapy (such as sodium
and weight loss counselling), with the goal of
ultimately building a standardised lifestyle
therapy programme to which physicians can
refer their hypertensive patients to the future.
Strengths and limitations of this study
- First study to examine a standardised stress
reduction group therapy, already funded in part
by the Ontario Health Insurance Plan, for the
management of high BP.
- Large sample size and use of randomised
controlled trial format minimises bias and maxi-
mises the opportunity to detect any BP-lowering
effect of MBSR.
- Due to the silent nature of high BP, the lack of
immediate positive perceptible feedback when BP
is lowered may hamper the reinforcement
necessary to make permanent lifestyle changes.
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Open Access ProtocolCochrane Collaboration Databases, the Canadian
Hypertension Education Program recommends lifestyle
modiﬁcation as a key strategy for the prevention and
treatment of hypertension (HTN).
1 Over 5 million
Canadians, part of a worldwide epidemic, are hyperten-
sive.
2 Data extrapolated from large population surveys
and prospective studies
34show that approximately
250000 Canadians with high-normal blood pressure
(BP) (systolic blood pressure (SBP) 120e139 mm Hg or
diastolic blood pressure (DBP) 80e89 mm Hg) will
develop full-blown high BP every year (BP $140/
90 mm Hg)dputting them at higher risk for heart
attack and stroke, necessitating the use of medications in
most of them. Preventing and controlling HTN is one of
the most cost-effective strategies for reducing the global
burden of premature cardiovascular disease and death.
5
Reducing SBP by just 3 mm Hg in the general popula-
tion has the potential to reduce stroke mortality by 8%
and coronary artery disease mortality by 5%.
67The
published ﬁndings of the InterStroke Study, one of the
largest studies of its type in the world, concluded
deﬁnitively that uncontrolled HTN is the single most
inﬂuential risk factor for stroke.
8
Stress has been associated with greater cardiovascular
risk and consideration of stress management is a recom-
mended intervention for hypertensives.
1 However,
speciﬁc stress management approaches are not well
validated for reducing HTN.
9e11 Stress management
therapies can be differentiated based on their approach
and delivery: single- or multicomponent approach and
individualised or group delivery. Certain therapeutic
approaches have been efﬁcacious for reducing BP in
subjects with hypertension: transcendental meditation
(TM) (a single-component, individualised therapy),
cognitive behavioural therapy (CBT) (a multicompo-
nent, individualised therapy) and, more recently,
contemplative meditation
12 (a multicomponent, group
therapy).
TM is a standardised form of meditation where an
individual repeats a mantra to move the mind towards
a higher state of concentration; this in turn leads to
a greater sense of relaxation and physiological calming.
9
Evidence indicates that single-component interventions
like TM are efﬁcacious in some conditions,
13e18
including HTN,
19 with possible long-term effects.
16 The
BP-lowering effect of TM has been further supported by
two meta-analyses, each suggesting TM can reduce both
SBP and DBP.
20 21 However, other meta-analyses have
suggested that the available clinical trials had signiﬁcant
‘methodological weaknesses and (were) potentially
biased by the afﬁliation of authors to the TM organiza-
tion’
9; thus, one must proceed with caution when eval-
uating if TM has a cumulative positive effect on lowering
BP.
9 CBT teaches subjects to be aware of stressors and to
re-evaluate negative life events.
22 In a carefully
controlled trial, Linden et al demonstrated that CBT
decreased BP in unmedicated participants with hyper-
tension.
23 While CBT, a multicomponent individualised
therapy, has demonstrated efﬁcacy in treating HTN, the
cost of administering this one-on-one therapy presents
a signiﬁcant barrier to its widespread use. Contemplative
meditation has demonstrated promising results;
however, limited research on the topic indicates that
more work must be done before ﬁnal conclusions can be
drawn.
12
Mindfulness-based stress reduction (MBSR), like CBT,
is a multicomponent therapy that encourages partici-
pants to modify their thought pattern through changing
their relationship and approach to stressors in their
lives.
24 However, unlike CBT, MBSR is a standardised
group therapy, which can be delivered to a heteroge-
neous population. It is now available for stress reduction
through some community and hospital complementary
medicine programmes, and in Ontario, it is covered in
part by the Ontario Health Insurance Plan. While CBT
can be viewed as an acute treatment option, MBSR works
as both an acute and preventive treatment as it provides
participants with strategies for working with the chal-
lenges and stressors in their lives.
25 MBSR teaches
participants to use mindfulness as an approach to adapt
to stress, pain and illness. In both clinical and non-clin-
ical populations, MBSR and related mindfulness-based
therapeutic practices have demonstrated beneﬁts for
chronic pain,
26e29 anxiety,
30e34 depression,
30 33e37
ﬁbromyalgia,
38e40 binge-eating
41 and psoriasis,
42 as well
as improved psychological well-being, immune function
and cortisol levels in cancer subjects,
43e54 psychological
well-being of cancer patient’s partners
55 and glycaemic
control in diabetic populations.
56 Three meta-analy-
ses
57e59 support the efﬁcacy of MBSR for improving both
physical and mental well-being in groups of subjects with
mixed medical illness. By bringing mindfulness to life
stressors, MBSR participants may more clearly see the
full context of a situation, have access to a broader range
of emotional responses and therefore cope with stressful
situations more effectively.
32
Preliminary information suggests that participating in
an MBSR programme also lowers BP
23 43 56 and improves
certain components of cardiovascular functioning.
60
Barnes et al initiated one of the earliest studies investi-
gating MBSR and BP; compared to control, those who
participated in a 2-month meditation intervention based
on MBSR techniques demonstrated lower SBP as
measured by an automated device:  4 mm Hg (inter-
vention) compared to +2 mm Hg (control).
61 A follow-
up study using ambulatory blood pressure monitoring
(ABPM) also found signiﬁcant differences in BP reduc-
tion for the meditation group at speciﬁc time periods
(eg, after school).
62 In an abstract, Van Wielingen et al
reported that patients with breast cancer who partici-
pated in MBSR had lower automated home BP
compared to those on wait-list control.
63 Examining the
treatment group alone, those with higher BP at baseline
demonstrated a greater decrease in SBP compared to
those with lower SBP at baseline.
63 A similar treatment
effect was described by Linden in subjects also starting
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The HARMONY Studywith higher BP levels.
64 Two studies by Carlson et al
demonstrated high rates of MBSR class attendance,
compliance and home meditation,
44 45 with the follow-
up study reporting consistent drops in clinic BP
persisting up to 1 year.
43 A randomised controlled trial
of an abbreviated 6-week programme using MBSR prin-
ciples for pain tolerance in normotensive university
students found improved pain tolerance and lower DBP
in both the treatment and control groups.
65 These early
studies point towards a BP-lowering effect from MBSR.
However, more rigorous methodology and larger sample
sizes are required to demonstrate whether MBSR can
truly lower BP.
Before a large outcome study can evaluate the use of
MBSR for the treatment of HTN, it is necessary to collect
data documenting efﬁcacy and treatment effect. The
HARMONY Study, a randomised controlled pilot trial
investigating the use MBSR for unmedicated stage 1
HTN, will test whether MBSR can signiﬁcantly lower BP
in unmedicated hypertensives. If found effective, the
HARMONY Study will provide evidence to support
a larger randomised controlled trial by evaluating the
feasibility and safety of MBSR as a complementary or
alternative treatment for HTN.
METHODS
Study design
The HARMONY Study is a randomised, prospective, two-
armed, wait-list controlled pilot trial. The intervention is
a standard 8-week MBSR programme. A wait-list
controlled trial design was chosen in order to model our
methodology after Linden et al.
23 The main outcome
measure is mean awake and 24 h systolic and diastolic
ambulatory blood pressure (ABP). The study population
consists of unmedicated men and women with stage 1
HTN. Based on the power analysis, the established
recruitment goal was 100 subjects. Screening baseline
ABPM determines hypertensive eligibility. Screening and
follow-up visits take place at Sunnybrook Health Sciences
Centre, Toronto, Ontario. All MBSR therapy is
conducted at the University Health Network’s Toronto
General Hospital, Toronto, Ontario.
Study participants
Eligible participants include adults aged 20e75 years
old, with mean awake systolic or diastolic ABP
$135 mm Hg or 85 mm Hg, or mean 24 h ABP
$130 mm Hg or 80 mm Hg. There must be no antihy-
pertensive use within 6 months of the screening/base-
line ABPM visit. We recognise the possibility that an
individual may choose to go off antihypertensive therapy
when they should not, and may potentially base this
decision on wanting to be in the HARMONY Study. In
these events, screening with the BPTru and ABPM
should capture those individuals whose BP is too high
and who should be on active antihypertensive therapy.
When screening BP is too high, individuals receive one-
on-one counselling with the primary investigator (ST)
about their BP, antihypertensive therapy and why they
could not be in the study. Using this methodology, we
hope to only recruit those who have moderately elevated
BP (stage 1) and do not require antihypertensive therapy
at the time of enrolment.
Study participants consist of those who meet the
screening criteria, are willing and able to participate in
the MBSR programme, can attend all necessary study
visits and complete all safety BP evaluations. Further
details regarding inclusion and exclusion criteria can be
found in box 1.
Study recruitment
The original planned recruitment rate was 25 subjects
every 6 months for a total of 100 subjects. Potential
participants have been identiﬁed through the clinical
practices and referral bases of BLA, MM and ST. Addi-
tional successful screening strategies have included
public information sessions, advertisements in local
Box 1 Study inclusion and exclusion criteria
Inclusion criteria:
1. Age 20e75 years.
2. Hypertensive as determined by ambulatory blood pres-
sure monitoring (ABPM) at baseline (daytime $135/
85 mm Hg or 24 h ABPM $130/80 mm Hg).
3. Willing and able to participate in the mindfulness-based
stress reduction (MBSR) programme.
4. Willing to be followed for safety blood pressure (BP)
checks if deemed necessary.
5. Willing to accept a possible waiting period of 12 weeks
for MBSR.
6. Written informed consent.
Exclusion criteria:
1. Use of antihypertensive within 6 months of the
screening ABPM.
2. Screening ofﬁce BP >180/100 mm Hg and ABPM
$160/100 mm Hg.
3. Diabetes.
4. Secondary hypertension.
5. Renal disease (Glomerular ﬁltration rate <60 ml/min or
overt nephropathy).
6. History of heart attack.
7. History of stroke or transient ischemic attack.
8. Re-vascularisation procedure.
9. Active malignant disease (except non-melanoma skin
cancer).
10. Epileptic seizure 6 months before the screening visit.
11. Congestive heart failure.
12. Severe liver disease.
13. Pregnancy or lactation period.
14. Participation in a clinical trail or receipt of investigational
compound or treatment in the 3 months prior to the
initial screening visit.
15. Planned elective surgery during the study period except
for cataract surgery.
16. Inability or unwillingness to perform three or four
ABPMs over 6 to 10 months.
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The HARMONY Studynewspapers and hospital posters. Screening is performed
using a validated automated BP device, the BpTRU
(VSM MedTech Ltd, Coquitlam, Canada). Individuals
with unmedicated ofﬁce BP $135/85 mm Hg are
invited to the next step of screening using 24 h ABPM.
Randomisation and study blinding
Randomisation to one of two study arms is done by
sealed envelope method using the permuted block
design, with blocks of two and four subjects to maintain
the adequacy of randomisation. A computer program
generated a random number sequence, which was used
to allocate subjects to the treatment or wait-list control
group. The randomisation schedule and sealed enve-
lopes were prepared by an individual who worked closely
with the Centre for Statistical Design and Analysis and
was not directly involved in the study. Blinding is not
possible for the HARMONY Study due to the wait-list
control design of the study. However, those delivering
the MBSR therapy are not informed as to which arm
subjects are randomised to.
Upon review of the screening ABPM results,
consenting subjects who meet study inclusion criteria are
randomised. Screening ABP is then used as the baseline
ABP for those enrolled in the study. Subjects are rand-
omised to either ‘early’ or ‘delayed’. Those randomised
to ‘early’ begin MBSR within 4 weeks of their screening/
baseline visit and repeat ABPM 12 weeks after the base-
line/screening visit (coinciding with completion of the
MBSR course). Those randomised to ‘delayed’ are wait-
listed for 12 weeks, repeat ABPM after that wait-list
period and subsequently begin MBSR within 4 weeks of
that ABPM (ﬁgure 1).
Primary outcome
The primary outcome measure is mean awake and 24 h
ABP. The primary objective of the HARMONY Study is to
compare mean awake and 24 h ABP between the treat-
ment and control arms at the 12-week post-baseline
primary assessment period (ﬁgure 1).
Secondary outcomes
Secondary outcomes include evaluating a within-group
effect of MBSR on ABP from pre- to post-MBSR inter-
vention. Persistence of effect 12 weeks after completing
the therapy will also be investigated (ﬁgure 1). Between-
and within-group comparisons of the effect of MBSR on
night-time ABP will also be assessed. The proportion of
subjects achieving BP targets (24 h ABP <130/80,
daytime ABP <135/85 mm Hg), those requiring the
initiation of medical therapy during the study and
adverse events will also be examined. The amount of
MBSR practiced outside the classroom will be analysed
(via participant diaries and homework logs) with respect
to change in BP to evaluate any doseeresponse interac-
tions. Associations between the effect of MBSR on ABP
and individual participant characteristics will also be
explored. This will be achieved by examining covariates
and incorporating them into a model with BP. See box 2
for further details regarding data collected at study visits.
The following questionnaires were included in the
study protocol to account for external confounders: (1)
Demographics and Lifestyle Questionnaire, (2) State-
Trait Anger Expression Inventory-2,
66 (3) Hospital
Anxiety and Depression Scale,
67 (4) Perceived Stress
Scale,
68 (5) Psychosocial Stress Questionnaire,
69 (6)
Exercise questionnaire, (7) Job Content Questionnaire,
70
Figure 1 HARMONY Study
design. ABPM, ambulatory blood
pressure monitoring; MBSR,
mindfulness-based stress
reduction.
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The HARMONY Study(8) Five-Facet Mindfulness Questionnaire,
71 (9) Clinical
Outcome Routine Evaluation Outcome Measure
72 and
(10) Toronto Mindfulness Scale.
73 All questionnaires are
administered at baseline with questionnaires 2, 4, 5 and 6
repeated at each study visit (ie, pre-MBSR, post-MBSR
and study close-out). The Toronto Mindfulness Scale is
administered after a period of meditation during the
second and seventh MBSR class. Planned future analyses
include evaluating the relationships between BP, gender
and responses from the questionnaires.
Intervention
MBSR is a multicomponent group therapy that provides
systematic training in mindfulness meditation as a self-
regulation approach to stress reduction and emotion
management. MBSR provides training in formal medi-
tation approaches, with the primary goal of cultivating
psychological resilience and resistance to stress. This is
achieved through fostering the quality of ‘mindfulness’,
deﬁned as the capacity to intentionally be in the present
moment without judgement.
24 MBSR teaches attendees
to approach stressful situations ‘mindfully’, allowing
them to identify what is occurring in their bodies and
minds and to step back from thoughts and feelings
during stressful situations. This affords participants the
opportunity to make wise choices with respect to
managing stressful situations, such as choosing to avoid
engaging in anxious worry that may otherwise escalate
into a cycle of stress reactivity and contribute to more
emotional distress.
24 74e76
The MBSR programme is delivered by trained thera-
pists to groups of 25e30 individuals and consists of 10
sessions: an introductory session, eight weekly sessions of
2.5 h and a 6 h intensive session/silent retreat held
between week 6 and 7 of the course on a Saturday or
Sunday. The MBSR programme incorporates four major
therapeutic elements: formal meditation, informal
mindfulness practice (such as bringing mindfulness to
daily activities), psychoeducational activities and self-
monitoring/reﬂection exercises. Each session also
includes group discussion. The development of mind-
fulness depends heavily upon regular and repeated
practice; thus participants commit to daily 45 min
homework meditation practice. Homework includes
both formal and informal meditation practices, as well as
self-observation questions. CDs are included to guide
attendees in daily formal meditation practice.
Participants learn new mindfulness practices each
week, as well as strategies to incorporate mindfulness
perspectives and approaches into daily activities. Some
examples of mindfulness practices include the body
scan, sitting meditation, mindful yoga, mindful walking,
mindful eating and loving kindness meditation. Partici-
pants are asked to complete a weekly homework log,
which tracks the number of minutes spent on formal
meditation practice and whether informal mindfulness
was practiced that day. Subjects are given new homework
logs each week when they return for class. Both adher-
ence to MBSR and class attendance are captured via the
homework logs. Homework logs are faxed weekly from
Toronto General Hospital to Sunnybrook Health
Sciences Centre where they are entered into the elec-
tronic database. HARMONY research staff are asked to
contact participants if more than two classes are missed
without explanation; this also affords study staff and
participants an opportunity to discuss causes for poor
class attendance. As the MBSR programme is stand-
ardised, subjects can be accommodated in other MBSR
classes throughout the course if necessary for sched-
uling. If too many classes are missed due to unforeseen
personal circumstances (and not due to lack of
commitment/interest by the study subject), then
attempts are made to accommodate them to another
MBSR course if possible.
Data collection
Study subject information is organised into individual
subject charts and uploaded electronically into a Micro-
soft Access Database ﬁle. All data of enrolled participants
are collected on denominated data collection forms,
Box 2 Baseline and ongoing data collection. All listed
measurements are collected baseline. All measurements
except for ECG are repeated at subsequent study visits
(before mindfulness-based stress reduction (MBSR),
following MBSR and at the 12-week study close-out)
Ambulatory blood pressure monitoring (ABPM):
- Participants wear an ambulatory blood pressure monitor
(model 90207, Spacelabs Medical Inc., Redmond,
Washington, USA).
- Blood pressure is recorded every 15 min during the day
and every 30 min between 23:00 and 7:00.
- Mean values calculated for systolic and diastolic blood
pressure.
Anthropometric measurements:
- Body weight and height measured to calculate body
mass index.
- Waist circumference measured at the top of the iliac
crest.
Ofﬁce blood pressure:
- Seated ofﬁce systolic and diastolic blood pressure
measured by BpTRU.
- Device takes six measurements every 2 min. Last ﬁve
measurements are averaged to determine the average
seated blood pressure.
Fasting serum samples:
- Plasma glucose, HbA1c, total cholesterol, HDL-choles-
terol, LDL-cholesterol, triglycerides, creatinine, electro-
lytes and liver enzyme levels.
Urine samples:
- Urine creatinine levels and microalbuminuria levels.
ECG
- To detect any abnormal heart rhythms and left ventricular
hypertrophy.
Blom K, How M, Dai M, et al. BMJ Open 2012;2:e000848. doi:10.1136/bmjopen-2012-000848 5
The HARMONY Studywith the contact information page and homework logs
being the only exceptions. Data from potential study
participants/screen fail participants are kept in
a screening log binder and a screen fail binder, respec-
tively. Coding of enrolled study participants is done by
study ID, executed in sequential in order (ﬁrst partici-
pant ¼ study ID 001). Data entry is completed by
a research assistant; future plans include auditing all
study charts and the study database at the end of the trial
to ensure data was entered accurately.
All study data are maintained in a secure location only
accessible to study related personnel; this includes lab
computers, which are accessible only through authenti-
cation with ID and password. Study data are shared with
family physicians or the Nephrology Research Group at
Sunnybrook Health Sciences Centre only with the
participant’s consent. All source information collected is
retained under the primary investigator (ST) as custo-
dian. After all data entry/data auditing are completed,
paper copies of study data will be stored at Iron Moun-
tain and destroyed after 25 years as per Health
Canada guidelines. Electronic study data will be kept in
the Microsoft Access Database until data analysis is
completed. Maintenance of study data and study conﬁ-
dentiality is done in full conformance with requirements
from the Sunnybrook Research Ethics Board, the
University Health Network Research Ethics Board and
Health Canada.
Safety
Lifestyle therapy is indicated for people who have stage 1
HTN (140e159/90e99 mm Hg) with no underlying
risk factors.
1 Linden has previously demonstrated the
role and safety of the wait-list control methodology and
determined it to be appropriate in studies with stage 1
and 2 hypertensives (140e179/90e109 mm Hg).
23 64 In
accordance with the Canadian standard of care for BP
management, all participants receive standard recom-
mendations of suggested lifestyle modiﬁcations for BP
management at study entry.
With participant consent, primary care physician(s)
are informed of their patient’s participation in the study.
Physicians are asked to delay the start of their patient’s
antihypertensive therapy until after they have completed
the study. If physicians believe that antihypertensive
should be initiated, they are asked to communicate their
decision to study staff before doing so. A letter updating
their patient’s progress, along with laboratory and ABPM
results, is sent to the primary care physician after each
study visit.
Automated ofﬁce BP safety assessments are included
to closely monitor subjects’ BP. The primary investigator
is notiﬁed if subjects exceed BP safety limits. If any of the
following conditions are discovered during study,
enrolment participants are withdrawn and treated: (1)
increases in ABP of 20/10 mm Hg or greater, (2)
accelerated HTN with an ofﬁce reading of 160/
100 mm Hg or greater, (3) macrovascular target organ
damage, (4) diabetes mellitus or (5) chronic kidney
disease (GFR<60 ml/min). Any subject started on anti-
hypertensive therapy during the study remains in the
study, and the initiation of medical therapy is recorded.
Sample size considerations
The main objective of this study was to assess the
difference in mean awake and 24 h systolic and diastolic
ABP 12 weeks post-baseline between the treatment and
wait-list control arm. The following calculations/analyses
are based on the work by Linden and the difference in
mean SBP between treatment groups measured as by
ABPM. Linden found a 6.1 mm Hg SBP drop from
baseline to the end of the primary assessment period for
participants in the immediate intervention group; the
wait-list control group showed a 0.9 mm Hg increase in
the same time interval
23 This resulted in a 7.0 mm Hg
difference between the two groups,
23 a relatively large
treatment effect, due in part to the use of subjects with
higher BP.
Unlike Linden who found BP rising in the control
group, more recent results from the Double Exposure
Study found that BP tended to fall over time, even in
unmedicated hypertensives. This may have been due in
part to an adoption of lifestyle changes.
77 78 Baseline
data from the unmedicated hypertensive cohort in the
Double Exposure Study demonstrated mean awake ABP
equal to 137/8568/5 mm Hg. After 1 year, mean awake
ABP had fallen to 133/8368/7 mm Hg. Based on these
results, it is reasonable to assume that BP will fall in the
HARMONY wait-list control arm.
Very conservative assumptions were made for the
HARMONY power analysis. A reduction of 2.0 mm Hg
for mean systolic ABP (half the change observed in the
Double Exposure Study) was assumed for the control
group (compared to the rise that Linden found
23). The
variance recorded in the study by Linden (9 mm Hg)
was used for the HARMONY power analysis; variance
higher than that recorded in the Double Exposure
cohort (8 mm Hg in only 35 subjects). Linden found
a BP difference of 7.0 mm Hg between the treatment
and control group. In our power analysis, the difference
between treatment and control groups was reduced from
the results of Linden to a more conservative value,
6 mm Hg. This value was chosen for two reasons: (1) it
was closer to ﬁndings from the meta-analysis of Dick-
inson
11 and (2) participants’ overall BP is anticipated to
be lower in the HARMONY Study (stage 1 hypertensives)
compared to Linden’s study (stage 1 and stage 2 hyper-
tensives).
23 Using a two-tailed two-sample t test, an esti-
mated group SD of 9.0 mm Hg and a signiﬁcance level
of 0.05, it was determined that a sample size of 37
subjects in each group would provide sufﬁcient power
(81%) to detect a SBP difference of 6.0 mm Hg between
the null hypothesis (both groups start with equal means
and have an equal a drop in SBP of 8.0 mm Hg) and the
alternative hypothesis (control group SBP will fall by
only 2.0 mm Hg). To account for potential dropouts
and subjects lost to analysis (25% lost in the study by
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23), the number of subjects was increased to 50
subjects per group (ﬁgure 2).
Statistical analysis
The primary outcome will be examined using an intent-
to-treat analysis. An intent-to-treat population is deﬁned
as all subjects in the study who completed at least one
session of MBSR. The primary outcome measure is mean
awake and 24 h systolic and diastolic ABP. ABP between
treatment and control will be compared by two-tailed two-
sample t test at the end of the 12-week primary outcome
period. Within-subject analysis of the effect of MBSR on
ABP will be performed by a paired t test. Persistence of
effect of MBSR on BP will be assessed using repeated
analysis of variance measures, comparing group differ-
ences between subsequent study visits (baseline, pre-
MBSR, post-MBSR and study close-out). The proportion
of subjects achieving BP targets will be analysed using c
2
tests. Multiple regression analyses will be employed to
assess differences in BP between subjects while adjusting
for covariates. Subjects may be started on antihyperten-
sive therapy during the study. If this leads to imbalance
between the study arms, a per-protocol analysis may be
performed to take this variable into account. All analyses
will be carried out using SAS V.9.1 (SAS Institute).
Ethical considerations
This research project is approved by the research ethics
board at Sunnybrook Research Institute (Toronto,
Canada) and the University Health Network Research
Ethics Board (Toronto, Canada). Planned data analyses
are in full conformance with the principles of the
‘Declaration of Helsinki’.
79 Conduct of the HARMONY
Study is fully adherent to the principles outlined in the
‘Guideline for Good Clinical Practice’ ICH Tripartite
Guideline (January 1997)
80 and in the second edition of
Tri-Council Policy Statement: Ethical Conduct for
Research Involving Humans.
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Dissemination plans
Data collection will be completed by early spring 2012.
Primary and secondary analysis will commence immedi-
ately after data monitoring is completed; publications will
be prepared for submission in the summer of 2012. Study
ﬁndings are also planned to be presented at the following
conferences: October 2012: Hypertension Canada, May
2013: American Society of Hypertension, June 2013:
European Society of Hypertension, September 2013:
International Society of Hypertension.
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